Crizanlizumab
Treatment for Sickle Cell Disorders
Typical Dosage: 5 mg/kg IV infusion monthly
Effectiveness
65%
Safety Score
65%
Clinical Trials
15
Participants
750
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
5 mg/kg IV infusion monthly
Time to Effect
Within weeks to 3 months
Treatment Duration
Lifetime (monthly infusions)
Evidence Quality
MODERATENumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Confidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$100,000
Monitoring:$2,000
Side Effect Mgmt:$300
Total Annual:$102,300
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$550,000/QALY
QALYs Gained
0.1
Outcome-Based Costs
Cost per Responder
$365,357
Comparison vs Hydroxyurea (and standard supportive care)
Cost Difference
+$102,000/year
More expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
No dominance
Crizanlizumab Outcomes
for Sickle Cell Disorders
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+28%
Common Side Effects
Nausea
+15%
Arthralgia
+15%
Back pain
+10%
Fever
+10%
Infusion-related reactions
+5%
Active Clinical Trials
4 active trials recruiting for Crizanlizumab in Sickle Cell Disorders
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
NCT04657822RECRUITINGPHASE4
130 participants
INTERVENTIONAL
Birmingham, United States +28 more
Started: Jun 10, 2021
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
NCT06439082RECRUITINGPHASE3
315 participants
INTERVENTIONAL
Birmingham, United States +17 more
Started: Oct 24, 2024
Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell Anemia
NCT05469828NOT YET RECRUITINGPHASE1, PHASE2
30 participants
INTERVENTIONAL
Started: Jul 1, 2024
Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
NCT03814746ACTIVE NOT RECRUITINGPHASE3
255 participants
INTERVENTIONAL
Atlanta, United States +58 more
Started: Jul 26, 2019
Completed Clinical Trials
8 completed trials for Crizanlizumab in Sickle Cell Disorders
Characteristics of Patients With Sickle Cell Disease
NCT05494541COMPLETED
540 participants
OBSERVATIONAL
East Hanover, United States
Started: Aug 30, 2021
An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients
NCT04662931COMPLETEDPHASE4
140 participants
INTERVENTIONAL
Guwahati, India +6 more
Started: Jul 14, 2021
Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients
NCT03474965COMPLETEDPHASE2
117 participants
INTERVENTIONAL
Birmingham, United States +34 more
Started: Oct 1, 2018
Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)
NCT03264989COMPLETEDPHASE2
57 participants
INTERVENTIONAL
Orange, United States +11 more
Started: Dec 19, 2017
A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism
NCT03938454COMPLETEDPHASE2
36 participants
INTERVENTIONAL
Birmingham, United States +12 more
Started: Oct 16, 2019
Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell Centers
NCT06662825COMPLETED
376 participants
OBSERVATIONAL
East Hanover, United States
Started: Dec 13, 2022
Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers
NCT05833022COMPLETED
297 participants
OBSERVATIONAL
Birmingham, United States +10 more
Started: Jul 30, 2021
Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease
NCT04053764COMPLETEDPHASE2
58 participants
INTERVENTIONAL
Birmingham, United States +23 more
Started: Dec 10, 2019